Tandem Diabetes Care Begins Enrollment for Insulin Pump Pivotal Trial
Tandem Diabetes Care has begun enrollment in trials for its touchscreen insulin pump.
The company announced the enrollment of the first patients for the at-home pivotal trial for the t:slim X2 Insulin Pump, which uses the company’s predictive low glucose suspend technology.
The study is a multi-center, randomized crossover trial comparing two three-week insulin pump use periods, one involving the pump and the other involving another pump without automated insulin suspension. It will include 90 type 1 diabetic patients aged six and above.